| Symbol | BLLN |
|---|---|
| Name | BILLIONTOONE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 1035 OBRIEN DRIVE, MENLO PARK, California, 94025, United States |
| Telephone | +1 650 460-2551 |
| Fax | — |
| — | |
| Website | billiontoone.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002070849 |
| Description | BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible - detecting and precisely quantifying genetic targets with single-molecule sensitivity. This superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine. We believe our novel smNGS platform technologies, combined with our AI-enhanced integrated workflow, allow us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy. Additional info from NASDAQ: |
ten Bosch John Roderick 🔴 sold 1.4K shares of BillionToOne, Inc. (BLLN) at $97.54 Transaction Date: Sep 09, 2026 | Filing ID: 000011
Read moreDirector Tsao David 🟡 adjusted position in 20.0K shares (2 derivative) of BillionToOne, Inc. (BLLN) at $100.00 ($2.1M) Transaction Date: Sep 09, 2026 | Filing ID: 000011
Read moreLynch Thomas P. 🟡 adjusted position in 20.0K shares (4 derivative) of BillionToOne, Inc. (BLLN) at $101.41 ($2.5M) Transaction Date: Sep 08, 2026 | Filing ID: 000067
Read moreDirector Atay Oguzhan 🟡 adjusted position in 20.0K shares (1 derivative) of BillionToOne, Inc. (BLLN) Transaction Date: Sep 08, 2026 | Filing ID: 000066
Read more📋 Tsao David (Officer) plans to sell 2K shares of BillionToOne, Inc. (at $97.54 each, total $171K) Filed: Sep 09, 2026 | ID: 006821
Read more📋 Tsao David (Officer) plans to sell 20K shares of BillionToOne, Inc. (at $102.27 each, total $2.0M) Filed: Sep 09, 2026 | ID: 006820
Read more📋 ten Bosch John Roderick (Officer) plans to sell 1K shares of BillionToOne, Inc. (at $97.54 each, total $138K) Filed: Sep 09, 2026 | ID: 006818
Read moreDirector Tsao David 🟡 adjusted position in 20.0K shares (1 derivative) of BillionToOne, Inc. (BLLN) Transaction Date: Sep 03, 2026 | Filing ID: 000009
Read more📋 Lynch Thomas P. (Officer) plans to sell 20K shares of BillionToOne, Inc. (at $99.24 each, total $2.0M) Filed: Sep 08, 2026 | ID: 006788
Read moreBillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07643896 | The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Condi… | — | Pregnant Individuals | Recruiting | 2026-01-10 | 2028-06-01 | ClinicalTrials.gov |
| NCT07096362 | Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancre… | Phase2 | Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | 2025-09-09 | 2030-09-30 | ClinicalTrials.gov |
| NCT05733689 | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | Phase1 | Gastroesophageal Adenocarcinoma | Recruiting | 2025-06-27 | 2027-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Nab Paclitaxel | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Irinotecan | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Leucovorin | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Oxaliplatin | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| 5-Fluorouracil | Other | Phase PHASE2 | Metastatic Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07096362 |
| Trastuzumab | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| Durvalumab | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| PEMBROLIZUMAB (alone or when added to a regimen above) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| NIVOLUMAB (alone or when added to a regimen above) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| DOCETAXEL and IRINOTECAN (alone or combined) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| PACLITAXEL with or without CARBOPLATIN | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFIRINOX | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFIRI | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFOX | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FLOT | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| Trastuzumab | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| Durvalumab | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| PEMBROLIZUMAB (alone or when added to a regimen above) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| NIVOLUMAB (alone or when added to a regimen above) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| DOCETAXEL and IRINOTECAN (alone or combined) | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| PACLITAXEL with or without CARBOPLATIN | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFIRINOX | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFIRI | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FOLFOX | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |
| FLOT | Other | Phase PHASE1 | Gastroesophageal Adenocarcinoma | RECRUITING | NCT05733689 |